Next Event in Series
Trailblazing Extrahepatic Targeting with Precise, Selective, & Potent Lipid-Based Vehicles
June 2-4, 2026 | Boston, MA
Discover, Formulate, & Manufacture Targeted, Stable, & Selective LNPs for mRNA, gRNA, CAR DNA & Beyond to Ensure Safety & Efficacy of Therapeutics Across Indications
LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly & Co/Verve Therapeutics and Bristol Myers Squibb/Orbital Therapeutics. Validating LNPs as a stand-out delivery vehicle for cell and gene therapies!
Returning to Boston in April 2026, the 5th LNP Formulation & Process Development Summit was an industry-led end-to-end meeting providing the latest scientific content to advance LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. This was your one-stop shop to hear insights on LNP discovery, analytics, formulation, process development and large-scale manufacturing.
With 3 focused streams, Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing, this was your opportunity to overcome challenges in achieving precise extrahepatic delivery, robust characterization of targeted LNPs and optimal formulations for ambient storage, all towards making LNP drug products more selective, safe and potent.
Uniting 180+ global LNP trailblazers, delegates gained exclusive access to LNP specific networking, partnership opportunities and collaborative discussions to drive the next-generation of LNPs towards the clinic.
-
This Summit showcases the latest advances in LNP formulation, analytical characterization, and process development, addressing key challenges such as extrahepatic targeting, immunogenicity, and scalable manufacturing. The program’s focus on integrating novel lipid chemistries, high-throughput analytics, and automation is important for the translation of RNA and gene editing therapies towards the clinic.
Annette Bak, Head, Advanced Drug Delivery, AstraZeneca
-
This meeting will provide key updates advances in oligonucleotide delivery, nanoparticle process development and analytics. The balance of industry and academic research being presented will span early discovery efforts through clinical successes of nanomedicines.
Luis Brito, Vice President, Delivery Platform, Beam Therapeutics
-
This conference stands out as the premier forum for LNP innovation, addressing critical challenges across the entire development pipeline from discovery to commercialization. The comprehensive coverage - spanning novel delivery mechanisms, formulation optimization, analytics, scale-up, and clinical translation - showcases breakthrough solutions to real-world problems in bringing LNP therapeutics to market. Both the calibre of presenters and the rich technical discussions deliver the innovative approaches needed to overcome development hurdles and accelerate patient impact.
Ching Kim Tye, Head, Drug Product Platform & Early Clinical Development, Sanofi
Attending Companies Included
Explore the 2026 Full Event Guide
- 50+ Data-Driven Case Studies on LNP Development for mRNA Vaccines, Cell Therapies, Gene Editing Payloads & Beyond
- 8+ Hours of Dedicated Networking to Connect with Fellow LNP Peers
- 3 Tracks of End-to-End Scientific Insights: Analytical Development & Characterization, Formulation & Delivery & Process Development & Manufacturing
- 3 Leading Scientific Advisory Board Members from AstraZeneca, Beam Therapeutics & Sanofi
- The World’s Largest LNP-Dedicated Forum
Snapshot of 2026 World Class LNP Speakers
Your 2026 Scientific Advisory Board
The Scientific Advisory Board of the 5th LNP Formulation & Process Development Summit brought together world-renowned experts whose leadership and insight ensure a program of unparalleled depth, relevance, and scientific excellence to accelerate LNP innovation.
The 2026 board included Annette Bak, Head of Advanced Drug Delivery (ADD) at AstraZeneca, Luis Brito, Vice President of Delivery Platform at Beam Therapeutics, and Ching Kim Tye, Head of Drug Product Platform and Early Clinical Development at Sanofi.
Together, they have helped shape the 2026 agenda and shared their expertise during the Panel Discussion: “Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients."
Attending Companies Included
Explore Related Events
Explore the Agenda
Discover the latest breakthroughs shaping LNP discovery, formulation, analytics, and manufacturing. Gain exclusive insights from industry leaders during data-driven presentations, interactive roundtables, and expert panel discussions.
Partner With Us
Showcase your offerings alongside other leading solution providers to a community dedicated to cutting-edge LNP innovation. Position your brand at the heart of the biopharma deals and partnerships defining RNA, cell, and gene therapy pipelines.
Join LNP Experts
Connect with LNP innovators, from across the globe and engage in the hottest conversations spanning the end-to-end development of LNP drug products. During the dedicated networking sessions, make critical connections and build meaningful collaborations.